Portal Hypertension and Cirrhosis

Aims & Scope

Portal Hypertension & Cirrhosis (PH&C) is an open access, peer-reviewed journal that aims to publish cutting-edge academic advances on innovative achievements and practice in the field of portal hypertension and cirrhosis.

The audience of the journal covers hepatologists, gastroenterologists, endoscopists, digestive surgeons, radiologists, oncologists, etc.

PH&C is the official journal of Chinese Portal Hypertension Alliance (CHESS).

This title is hosted by Chinese Medical Association (CMA), and supported by National Medical Center for Infectious Diseases of China.

Readership: Hepatologists, Gastroenterologists, Endoscopists, Digestive Surgeons, Radiologists, Oncologists, etc.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)
• Web of Science

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Plagiarism url
• Preservation url
• Apc url
• License

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Medicine, ensuring accessibility and quality in research dissemination.

This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 2,534.00 EUR. Learn more.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Antibiotic prophylaxis in cirrhosis patients with upper gastrointestinal bleeding: An updated systematic review and meta‐analysis

  Citation: 16

  Authors: Yu Jun, Chin Kimg, Yuen Lin, Yoko, Yew Chong, Edwin, Juan G.

• Sarcopenic obesity in liver disease: Handling both sides of the penny

  Citation: 13

  Authors: Yangyang, Binxin, Xiaoyu, Mingyu, Yifan, Wanting, Gaoyue, Lihong, Zihan, Xiaofei, Chao

• Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives

  Citation: 11

  Authors: Lei, Giovanni, Christopher D., Luca, Xiaolong, Ming‐Hua

• Nonalcoholic fatty liver disease (NAFLD) among older adults

  Citation: 11

  Authors: Panyavee, Sombat

• Nonselective beta‐blockers reduce mortality in patients with acute‐on‐chronic liver failure

  Citation: 10

  Authors: Anand V., Madhumita, Karan, Juned A., Baqar A., Sowmya, Sameer, Mithun, Rajesh, Nageshwar D., Padaki N.

• Tolerance and acceptance of hepatic venous pressure gradient measurement in cirrhosis (CHESS1904): An international multicenter study

  Citation: 9

  Authors: Jun‐Hui, He, Haijun, Lei, Necati, Zi‐Niu, Xun, Shuangxi, Xujun, Huaping, Xiaoliang, Zhengcong, Yajin, Zhongwei, Jianting, Qiaohong, Xiaole, Huiling, Kefeng, Chao, Wei, Xiuqing, Haixin, Changzeng, Jitao, Bo, Chunqing, Xiaoling, Guangchuan, Shengjuan, Ruihang, Li, Hui, Qingli, Xue, Feng, Qin, Linpeng, Ying, Jian, Kohei, Sawako, Norifumi, He, Li, Wei, Guo, Lei, Xudong, Qingliang, Hailong, Xiaoli, Rafael O., Adriano, Giulliano, Yubao, Zebin, Mingsheng, Xiaoyong, Jun, Feng, Yang, Shengjuan, Linke, Xiao, Xiaolong

• The natural history of patients with compensated cirrhosis and elevated hepatic venous pressure gradient

  Citation: 8

  Authors: Andrew, Ali, Don C.

• Traditional Chinese medicine targets on hepatic stellate cells for the treatment of hepatic fibrosis: A mechanistic review

  Citation: 7

  Authors: Dengcheng, Lu, Yanqin, Nisma L. B., Jingru, Yanping, Mingyu

• Global burden trends of MAFLD‐related liver cancer from 1990 to 2019

  Citation: 7

  Authors: Hangkai, Zhening, Miao, Yishu, Chengfu

• T cells and liver fibrosis

  Citation: 6

  Authors: Ruonan, Zheng, Bin